3634 results for «209»
3634 results
Angiography-based physiology: time to change your routine clinical practice?
20 May 2026 – From EuroPCR 2026
This session offers a critical appraisal of angiography-based physiology, with a focus on virtual fractional flow reserve (vFFR) technology. It reviews the latest clinical evidence, including insights from the FAST study programme and the FAST III randomised controlled trial. Gain a clear understanding of current guideline...
The metal-free strategy: shaping the new era of hybrid vessel restoration with DCB and BRS
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores the emerging metal-free strategy in coronary intervention, combining drug-coated balloons (DCB) and bioresorbable scaffolds (BRS) to support a “leave-nothing-behind” approach to vessel restoration.
It focuses on lesion preparation, scaffold sizing and deployment, and the integration of hybrid therapies to optimise procedural outcomes....
Beyond visualisation: the value and future of 4D intracardiac echocardiography in tricuspid repair and replacement
20 May 2026 – From EuroPCR 2026
Explore the transformative role of 4D intracardiac echocardiography in guiding tricuspid edge-to-edge repair (TEER) and valve replacement for tricuspid regurgitation. This session highlights how real-time, high-resolution imaging enhances procedural efficiency and safety, reducing reliance on general anesthesia and shortening procedure times compared to traditional imaging modalities.
Where to leave less behind: non-invasive CT and angiography-derived physiology for DCB lesion selection
20 May 2026 – From EuroPCR 2026
This session elucidates the role of non-invasive coronary CT and angiography-derived physiology in guiding lesion selection for drug-eluting balloon PCI. It emphasises integrating anatomical and physiological data to refine lesion preparation, strategy, and validation beyond angiography, and identifies scenarios where DEB PCI may not be optimal,...
Rethinking stentless PCI strategy - Improving outcomes with Bioadaptor
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores contemporary PCI strategies through the concept of stentless intervention using the Bioadaptor device in complex coronary disease.
It highlights the bioadaptive design features of Bioadaptor and reviews the supporting clinical evidence, with a focus on how this technology may influence procedural outcomes.
The...
Reshaping what's possible in complex PCI with advanced sirolimus technology
21 May 2026 – From EuroPCR 2026
Focused on advancing complex PCI, this session explores strategies to minimise metal use through advanced sirolimus technologies and drug-coated balloon (DCB) therapies. It highlights the biological and pharmacokinetic characteristics of DCBs, key device design considerations, and practical approaches to less-metal PCI. Clinical cases illustrate challenges such...
How to become a CHAMPION in LAA closure
19 May 2026 – From EuroPCR 2026
This session reviews the latest CHAMPION AF trial data and its implications for left atrial appendage (LAA) closure in patients with atrial fibrillation.
It explores how emerging evidence may influence clinical practice and patient selection, and how LAA closure could evolve across different atrial fibrillation populations.
A recorded...
From 3D coronary imaging to calcium modification: the future of PCI starts now
21 May 2026 – From EuroPCR 2026
The integration of advanced imaging and calcium modification techniques is reshaping percutaneous coronary intervention (PCI), offering new ways to plan and optimise complex procedures.
This EuroPCR 2026 session explores how 3D coronary imaging extends beyond conventional angiography to improve procedural planning and decision-making. It highlights the role...
On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial
05 Mar 2023
Mirvat Alasnag provides her take on this clinical trial presented by Yundai Chen at the American College of Cardiology Scientific Session (ACC.23/WCC).
Author
MASTER-DAPT: “the MASTER of high-bleeding risk trials”
28 Aug 2021
Marco Valgimigli (Lugano, Switzerland) presented the results of the MASTER DAPT trial on Saturday, August 28, in a Hot Line session of the ESC Congress 2021. Luis G. Ortega-Paz provides his PICOT & SWOT analysis of this study.
Author
SMT’s Hydra TAVR Valve demonstrates sustained safety, durability, and hemodynamic performance at 5 Years
19 Nov 2025
TRISCEND II trial: Randomized comparison of transcatheter valve replacement vs. optimal medical therapy for severe tricuspid regurgitation
04 Nov 2024
Alex Sticchi provides his take on the results of the TRISCEND II trial presented by Susheel K. Kodali and Suzanne V. Arnold at TCT 2024 in Washington.
Also watch the interview with Susheel K. Kodali
Author
Harmonising optimal strategy for treatment of coronary artery diseases – bleeding risk: HOST-BR
29 Mar 2025
Daniele Giacoppo and Nicola Ammirabile provide their take on the main results of the HOST-BR trial, presented by Hyo-Soo Kim at ACC.25 in Chicago.
Author
Author
HOST-EXAM:10-year follow-up of clopidogrel vs aspirin monotherapy in stable CAD after PCI with drug-eluting stent
30 Mar 2026
Nicola Ryan provides her take on the 10-year follow-up of the HOST-EXAM, which was presented by Hyo-Soo Kim at ACC.26 in New Orleans.
Author
